Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

Two months af­ter an­nounc­ing Clay Sie­gall’s ar­rival in the C-suite, Mor­phim­mune has nabbed more funds to take its tar­get­ed can­cer ther­a­py bet to­ward the clin­ic.

The fledg­ling biotech filed a $15 mil­lion eq­ui­ty round, from 11 in­vestors, with the SEC this week. Mor­phim­mune did not re­spond to End­points News as of pub­li­ca­tion time. The fi­nanc­ing comes through as Sie­gall set­tles in­to his first post-Seagen role as CEO, pres­i­dent and board mem­ber of Mor­phim­mune.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN